amyotrophic lateral sclerosis Archives -

Amylyx Pharmaceuticals’ efforts to bring its amyotrophic lateral sclerosis therapy AMX0035 to market in the US have run

Amylyx bags first approval for ALS drug Albrioza

https://pharmaphorum.com/news/amylyx-bags-first-approval-for-als-drug-albrioza/

Cumulus puts its digital biomarkers for CNS diseases to the test

Phil Taylor Alzheimer's disease, amyotrophic lateral sclerosis, Cumulus Neuroscience, dementia, digital, digital biomarker, digital health, neurology 0 Comment

Cumulus Neuroscience has started a pair of clinical trials to gauge the value of a panel of physiological

Cumulus puts its digital biomarkers for CNS diseases to the test

https://pharmaphorum.com/news/cumulus-puts-its-digital-biomarkers-for-cns-diseases-to-the-test/

Market Access/ News/ News

Patients dismayed as FDA advisors narrowly reject Amylyx’ ALS drug

Phil Taylor Amylyx, amyotrophic lateral sclerosis, fda, neurodegenerative disease, neurology 0 Comment

By a narrow margin, an FDA advisory committee has voted against approval of Amylyx’ experimental medicine for amyotrophic

Patients dismayed as FDA advisors narrowly reject Amylyx’ ALS drug

https://pharmaphorum.com/news/patients-dismayed-as-fda-advisors-narrowly-reject-amylyx-als-drug/

Market Access/ News/ News

Amylyx slumps on non-committal FDA reviewer assessment of ALS drug

Phil Taylor Amylyx, amyotrophic lateral sclerosis, central nervous system, neurodegenerative disease 0 Comment

Shares in Amylyx Pharma slid today after the FDA published a less-than-enthusiastic assessment of its amyotrophic lateral sclerosis

Amylyx slumps on non-committal FDA reviewer assessment of ALS drug

https://pharmaphorum.com/news/amylyx-slumps-on-non-committal-fda-reviewer-assessment-of-als-drug/

Market Access/ News/ News

Amylyx preps filing for its ALS drug after FDA feedback

Phil Taylor Amylyx, amyotrophic lateral sclerosis, central nervous system, neurology 0 Comment

Just a few months ago, Amylyx was talking about having to complete another clinical trial before it could

Amylyx preps filing for its ALS drug after FDA feedback

https://pharmaphorum.com/news/amylyx-preps-filing-for-its-als-drug-after-fda-feedback/

News/ News/ R&D

AZ’s Alexion plans hit a snag as Ultomiris flunks ALS trial

Phil Taylor Alexion, amyotrophic lateral sclerosis, AstraZeneca, complement therapeutics, neurodegenerative disease, Soliris, UCB, Ultomiris, zilucoplan 0 Comment

It has only been a month since AstraZeneca’s $39 billion takeover of Alexion was completed, but the new

AZ’s Alexion plans hit a snag as Ultomiris flunks ALS trial

https://pharmaphorum.com/news/azs-alexion-takeover-hits-a-snag-as-ultomiris-flunks-als-trial/

Two cast gold bars of different weights.

News/ News/ R&D

Clene goes public with gold-based neurology nanotechnology

Richard Staines amyotrophic lateral sclerosis, multiple sclerosis, neurology, Parkinson's 0 Comment

Biotech Clene Nanomedicine has gone public with a mission to use nanotherapeutics that will use gold to treat

Clene goes public with gold-based neurology nanotechnology

https://pharmaphorum.com/news/clene-goes-public-with-gold-based-neurology-nanotechnology/

Market Access/ News/ News

Lilly to buy private biotech Disarm Therapeutics for up to $1.36bn

Richard Staines amyotrophic lateral sclerosis, Disarm Therapeutics, Eli Lilly, multiple sclerosis, NICE 0 Comment

Eli Lilly is to buy the private biotech Disarm Therapeutics, which is working on a new class of

Lilly to buy private biotech Disarm Therapeutics for up to $1.36bn

https://pharmaphorum.com/news/lilly-to-buy-private-biotech-disarm-therapeutics-for-up-to-1-36bn/

News/ News/ R&D

Biogen teams up with gene-editing startup Scribe on ALS programme

Phil Taylor amyotrophic lateral sclerosis, Biogen, central nervous system, CRISPR/Cas9, licensing, neurodegenerative disease, Scribe Therapeutics 0 Comment

Scribe Therapeutics, a start-up focusing on gene-editing using CRISPR/Cas9, has burst onto the biotech scene with a $415

Biogen teams up with gene-editing startup Scribe on ALS programme

https://pharmaphorum.com/news/biogen-teams-up-with-gene-editing-startup-scribe-on-als-programme/

Trending

amyotrophic lateral sclerosis

Login